Cue Biopharma, Inc.

Day range

$17.89 – $18.85

Open

$18.48

Prev close

$18.66

Volume

143.76K

Market cap

$135.55M

Shares out

7.26M

P/E

—

P/S

3.60

P/B

58.68

P/FCF

—

ROE

-7104.2%

ROA

-534.4%

Debt/Equity

0.42

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 21, 2026

  On September 20, 2026, the Company announced positive topline data from a Phase 2 clinical trial of CUE-221 in CSU conducted in China by Genesis Life Sciences, an affiliate of Ascendant Health Ltd. This Phase 2 clinical trial enrolled 145 participants with moderate to severe CSU whose disease remained inadequately controlled despite treatment with H1-antihistamines.

• Equity compensation grantAug 3, 2026

  the Board granted to Mr. Ahlers, under the Company's 2026 Inducement Stock Incentive Plan (the "Plan"), as an inducement material to Mr. Ahlers acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), (i) nonstatutory stock options (the "Initial Option") to purchase 51,00 shares of the Company's common stock and (ii) a restricted stock unit award for 25,500 shares of the Company's common stock (the "Initial RSU" and together with the Initial Option, the "Initial Grants"). The Initial Option has an exercise price per share equal to $30.40, the closing price of the Company's common stock on the Nasdaq Capital Market on the Effective Date. The Initial Grants will vest in equal quarterly installments over four years from the Effective Date.

• Equity compensation grantJul 10, 2026

  the Company's board of directors (the "Board") granted on July 9, 2026 (the "Grant Date") an aggregate of 1,064,492 restricted stock units ("RSUs") to its employees and executive officers as one-time grants with time and performance-based vesting. Executive officers, Shao-Lee Lin, the Company's President and Chief Executive Officer, received an award of 655,074 RSUs; Sumita Ray, the Company's Chief Legal and Compliance Officer and Corporate Secretary, received an award of 109,178 RSUs; and Michael Meluzio, the Company's Principal Accounting Officer, received an award of 81,884 RSUs.

• Warrant or conversionJun 3, 2026

  The Company's stockholders approved, in accordance with Nasdaq Listing Rule 5635(a), (c) and (d), the issuance of shares of common stock upon the exercise of certain warrants issued by the Company in May 2026 in connection with a licensing transaction and related private placement.

• Director appointmentJun 2, 2026

  On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified. Mr. Camardo was appointed as chair of the Nominating and Corporate Governance Committee of the Board and as a member of the Audit Committee of the Board (the "Audit Committee") and the Compensation Committee of the Board (the "Compensation Committee"), and Ms. Meehan was appointed as chair of the Audit Committee and as a member of the Compensation Committee.

Days to cover

1.1

Short interest

702.2K

Avg volume

666.08K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care
  positiveGlobeNewswire Inc.· Sep 30, 2026
• Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
  neutralGlobeNewswire Inc.· Sep 23, 2026
• Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
  positiveGlobeNewswire Inc.· Jul 13, 2026
• Cue Biopharma Announces $50.0 Million Private Placement
  positiveGlobeNewswire Inc.· Jul 9, 2026
• Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  positiveGlobeNewswire Inc.· May 7, 2026